Liraglutide mimics the natural GLP-1 hormone, which slows gastric emptying, reduces appetite, and enhances feelings of fullness
Previs, S
There has been a bit of skepticism surrounding compounded semaglutide among the general public recently, mostly due to the FDA warning issued on July 26th, 2024
Add electrolytes if you are losing fluids through exercise or side effects

In semaglutides case: Novo Nordisk obtained a genus patent covering semaglutide as a compound, with the usual 20year protection.[19][20] Later, it filed a second patent on a closely related version intended to prolong exclusivity, along with a series of secondary patents on formulations and delivery devices.[21][14] The Delhi High Court, examining Novos suit against Indian companies like Dr Reddys, held that this second patent amounted to double patenting and evergreening , which is barred under Indias Patents Act (Section 3(d)).[20][22][19] Because India explicitly prohibits evergreening, the court refused to block Indian firms from manufacturing and exporting semaglutide while maintaining restrictions on incountry sales tied to remaining patent issues.[23][20] Key point: Courts in India have openly described parts of Novos semaglutide strategy as evergreeningextending monopoly protection beyond what a single invention normally deserves